5-Hydroxymethylcytosine Modifications in Circulating Cell-free DNA: Frontiers of Cancer Detection, Monitoring, and Prognostic Evaluation

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2025 Mar 7

PMID 40055844

Authors

Danjun Song

Zhou Zhang

Jiaping Zheng

Wei Zhang

Jiabin Cai

Affiliations

Soon will be listed here.

Abstract

Developing accurate, clinically convenient, and non-invasive methods for early cancer detection, monitoring, and prognosis assessment is essential for improving patient survival rates, enhancing quality of life, and reducing the socioeconomic burden associated with cancer. This goal is critical in precision oncology. Genetic and epigenetic alterations in circulating cell-free DNA (cfDNA) have emerged as transformative tools for advancing early cancer detection, monitoring, and improving patient outcomes. Among these, 5-hydroxymethylcytosine (5hmC) modifications in circulating cfDNA stand out as promising epigenetic markers, offering insights into cancer initiation, progression, metastasis, and prognosis across various cancer types, such as lung cancer, colorectal cancer, and hepatocellular carcinoma. This review comprehensively explores the biology and sequencing methodologies of 5hmC, emphasizing their potential in cancer screening, diagnosis, treatment monitoring, and prognostic assessment. It highlights recent advancements in cfDNA-derived 5hmC signatures' applications, addressing their strengths and limitations in the context of clinical translation. Furthermore, this review outlines key challenges and future directions for integrating 5hmC modifications in cfDNA into routine clinical practice, facilitating personalized and non-invasive cancer management.

References

Singal A, Llovet J, Yarchoan M, Mehta N, Heimbach J, Dawson L . AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78(6):1922-1965. PMC: 10663390. DOI: 10.1097/HEP.0000000000000466. View

Ostrom Q, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan J . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. 2021; 23(12 Suppl 2):iii1-iii105. PMC: 8491279. DOI: 10.1093/neuonc/noab200. View

Cai Q, Zhang Z, Cui X, Zeng C, Cai J, Cai J . PETCH-DB: a Portal for Exploring Tissue-specific and Complex disease-associated 5-Hydroxymethylcytosines. Database (Oxford). 2023; 2023. PMC: 10311472. DOI: 10.1093/database/baad042. View

Jevsinek Skok D, Hauptman N . Steadfast Toll Like Receptor 4 () 5-Hydroxymethylcytosine Levels in Cell-Free DNA: A Promising Consistency Marker for Colorectal Cancer Patients. Genes (Basel). 2023; 14(8). PMC: 10454843. DOI: 10.3390/genes14081636. View

Chen H, Zhang W, Zhang L, Yang P, Li F, Yang Z . 5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients. Clin Epigenetics. 2021; 13(1):33. PMC: 7879534. DOI: 10.1186/s13148-020-00973-8. View

Li W, Zhang X, Lu X, You L, Song Y, Luo Z . 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 2017; 27(10):1243-1257. PMC: 5630683. DOI: 10.1038/cr.2017.121. View

Chiu B, Chen C, You Q, Chiu R, Venkataraman G, Zeng C . Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma. NPJ Genom Med. 2021; 6(1):11. PMC: 7878492. DOI: 10.1038/s41525-021-00179-8. View

Dang Y, Hu D, Xu J, Li C, Tang Y, Yang Z . Comprehensive analysis of 5-hydroxymethylcytosine in zw10 kinetochore protein as a promising biomarker for screening and diagnosis of early colorectal cancer. Clin Transl Med. 2020; 10(3):e125. PMC: 7418801. DOI: 10.1002/ctm2.125. View

Fowler A, Mankoff D, Joe B . Imaging Neoadjuvant Therapy Response in Breast Cancer. Radiology. 2017; 285(2):358-375. DOI: 10.1148/radiol.2017170180. View

10.

Shen Y, Ou J, He B, Yang J, Liu H, Wang L . 5-Hydroxymethylation alterations in cell-free DNA reflect molecular distinctions of diffuse large B cell lymphoma at different primary sites. Clin Epigenetics. 2022; 14(1):126. PMC: 9555108. DOI: 10.1186/s13148-022-01344-1. View

11.

Shao J, Wang S, West-Szymanski D, Karpus J, Shah S, Ganguly S . Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia. Sci Rep. 2022; 12(1):12410. PMC: 9300744. DOI: 10.1038/s41598-022-16685-3. View

12.

Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W . Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019; 68(12):2195-2205. PMC: 6872444. DOI: 10.1136/gutjnl-2019-318882. View

13.

Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y . Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther. 2024; 9(1):132. PMC: 11102923. DOI: 10.1038/s41392-024-01823-2. View

14.

West-Szymanski D, Zhang Z, Cui X, Kowitwanich K, Gao L, Deng Z . 5-Hydroxymethylated Biomarkers in Cell-Free DNA Predict Occult Colorectal Cancer up to 36 Months Before Diagnosis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. JCO Precis Oncol. 2024; 8():e2400277. PMC: 11729496. DOI: 10.1200/PO.24.00277. View

15.

Pastor W, Pape U, Huang Y, Henderson H, Lister R, Ko M . Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature. 2011; 473(7347):394-7. PMC: 3124347. DOI: 10.1038/nature10102. View

16.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

17.

Cali D, Kim J, Ghose S, Alkan C, Mutlu O . Nanopore sequencing technology and tools for genome assembly: computational analysis of the current state, bottlenecks and future directions. Brief Bioinform. 2018; 20(4):1542-1559. PMC: 6781587. DOI: 10.1093/bib/bby017. View

18.

Liu H, Tang T, Zhang H, Ting W, Zhou P, Luo Y . Identification of a 5-Hydroxymethylation Signature in Circulating Cell-Free DNA for the Noninvasive Detection of Colorectal Cancer. J Oncol. 2022; 2022:3798741. PMC: 9581595. DOI: 10.1155/2022/3798741. View

19.

van den Bent M, Geurts M, French P, Smits M, Capper D, Bromberg J . Primary brain tumours in adults. Lancet. 2023; 402(10412):1564-1579. DOI: 10.1016/S0140-6736(23)01054-1. View

20.

Chen L, Abou-Alfa G, Zheng B, Liu J, Bai J, Du L . Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. Cell Res. 2021; 31(5):589-592. PMC: 8089097. DOI: 10.1038/s41422-020-00457-7. View